Safety, Efficacy, and Pharmacokinetics of Agalsidase Alfa in Treatment-Naive Chinese Patients with Fabry Disease: 52-Week Phase 3, Open-Label, Single-Arm Study.
Oct 2026· Advances in Therapy· 0 citations· 20 references
Medicine
TL;DR
Data from this 52-week study support the use of agalsidase alfa as a long-term treatment option for Chinese patients with Fabry disease and safety, efficacy, and pharmacokinetic profiles were consistent with studies in other populations.
Abstract
INTRODUCTION
Clinical data on the efficacy, tolerability, and pharmacokinetics of agalsidase alfa in Chinese patients with Fabry disease are limited. We evaluated the safety, efficacy, and pharmacokinetics of agalsidase alfa in Chinese patients who are treatment-naive over 52 weeks.
Methods
This was an open-label, non-randomized, single-arm, multicenter (six centers in China) phase 3 study. Patients with Fabry disease (aged 7-65 years; either sex) received agalsidase alfa 0.2 mg/kg intravenously (every other week for up to 52 weeks). The primary endpoint was the incidence of serious treatment-emergent adverse events (TEAEs). Secondary endpoints included the incidence of TEAEs, changes from baseline in estimated glomerular filtration rate (eGFR), left ventricular mass index (LVMI), left ventricular ejection fraction (LVEF), and agalsidase alfa pharmacokinetics.
Results
Overall, 20 patients were enrolled (May 2022 to January 2024) and received ≥ 1 dose of agalsidase alfa. The median number of infusions was 27; median exposure duration was 12.0 months. Agalsidase alfa was generally well tolerated. Two patients (10.0%) reported one serious TEAE each (sepsis, ectopic pregnancy). All patients reported ≥ 1 TEAE, most of which were mild or moderate (98.2%); nine patients (45.0%) had ≥ 1 TEAE assessed as related to treatment. Baseline eGFR, LVMI, and LVEF were 118.8 (21.4) mL/min/1.73 m2, 38.0 (11.2) g/m2.7, and 66.8% (4.9), respectively. Renal function and cardiac structure and function remained relatively stable over 52 weeks; mean (SD) changes in eGFR, LVMI, and LVEF from baseline were 4.1 (12.5) mL/min/1.73 m2, 0.56 (8.71) g/m2.7, and 0.8% (3.3%), respectively. Agalsidase alfa exposure (area under the concentration-time curve and maximum serum concentration) was generally similar at week 0 and at week 28.
Conclusions
Data from this 52-week study support the use of agalsidase alfa as a long-term treatment option for Chinese patients with Fabry disease. Safety, efficacy, and pharmacokinetic profiles were consistent with studies in other populations. Graphical Abstract available for this article.
CLINICALTRIALS
GOV ID
NCT04974749.
INTRODUCTION
Older patients with relapsing multiple sclerosis (PwRMS) are often underrepresented in clinical trials, limiting evidence on the safety and effectiveness of disease-modifying therapies. This study characterized the safety and effectiveness of short-course treatment with cladribine tablets (CladT) over 24 m...
J. Katz, Amy Gutierrez, L. Goldstick et al.· Neurological Therapeutics· 0 citations
ICP-332 is a novel, orally administered TYK2 inhibitor with high selectivity, intended for the treatment of immune inflammatory diseases such as atopic dermatitis, psoriatic arthritis, inflammatory bowel disease and lupus. This Phase I study assessed its safety, pharmacokinetics, pharmacodynamics, and food effect i...
Heng-Li Zhao, Yi-Lin Wei, Yu Jiang et al.· Frontiers in Pharmacology· 0 citations
Ofatumumab, a fully human anti-CD20 monoclonal antibody, has shown superior efficacy and a comparable overall safety profile to teriflunomide in the pivotal ASCLEPIOS I/II trials in people living with relapsing multiple sclerosis (plwRMS). However, data on the efficacy and safety of ofatumumab, a high-efficacy th...
BACKGROUND
Anti-glomerular basement membrane disease (GBM) is the most severe type of autoimmune kidney diseases, and is associated with the overactivation of the complement cascade. We aimed to evaluate the efficacy and safety of eculizumab, a complement C5 blocker that targets terminal pathways, in patients with anti...
Huang Kuang, Xiao-Yu Jia, Pei Chen et al.· Nephrology, Dialysis and Tra...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.